Angiotensin II receptor antagonists for the treatment of heart failure: What is their place after ELITE-II and VaI-HeFT?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue 2, 2001, Pages 89-92

  McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angiotensin II; Antagonists; Clinical trials; Heart failure; Receptor

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 0035383244     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2001.017     Document Type: Article

References (20)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.
4. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;341:709-17.
5. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study. N Engl J Med 1999;100:2312-8.
6. Pitt B, Chang P, Timmermans PBM. Angiotensin-II receptor antagonists in heart failure - Rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovascular Drugs and Therapy 1995;9:693-700.
7. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 1997;349:747-52.
8. Pitt B, Poole-Wilson P, Segal R et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999;5:146-54.
9. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
10. Tsuyuki RT, Yusuf S, Rouleau JL et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Card 1997;13:1166-74.
11. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.
12. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-reccptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-60.
13. Wolny A, Clozel JP, Rein J et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circulation Research 1997;80:219-27.
14. Voors AA, Pinto YM, Buikema H et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998;125:1028-32.
15. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JMC, McMurray JJV. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:1056-61.
16. Siragy HM, Carey RM. Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2001;1:99-103.
17. Berry C, Norrie J, McMurray J. Are Angiotensin II receptor blockers more efficacious than placebo in heart failure? implications of ELITE-2. Am J Cardiol 2001;87:606-7.
18. Horton R. From star signs to trial guidelines. Lancet 2000; 55:1033-4.
19. Pfeffer MA, McMurray J, Leizorovicz A et al. Valsartan in acute myocardial infarction trial - VALIANT: rationale and design. Am Heart J 2000;140:727-50.
20. Swedberg K, Pfeffer M, Granger C et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999;3:5276-82.